Denali Therapeutics
-
FDA presses pause on test of Alzheimer’s drug from Denali before study even starts
The FDA placed a clinical hold on Denali Therapeutics’ application to begin Phase 1 testing of an antibody drug for Alzheimer’s disease. The Denali drug uses the biotech’s proprietary technology to deliver therapeutic cargo across the protective blood-brain barrier.
-
Flagship Pioneering forges ahead with $618M capital raise
The capital raise is the culmination of a year that was punctuated with two of its portfolio companies filing initial public offerings and the hire of J.P. Morgan veteran Stephen Berenson.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Startups, BioPharma, Policy, Payers
New standards for genetic testing, get your fill of the Denali dream team (Morning Read)
Get the latest: FDA outlines genetic testing standards, everyone writes about Denali and California moves on a batter vaccination bill.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
